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Contemporary advancements have had little impact on the treatment of gastric cancer (GC), the world’s second
highest cause of cancer death. Agents targeting human epidermal growth factor receptor mediated pathways have
been a common topic of contemporary cancer research, including monoclonal antibodies (mAbs) and receptor
tyrosine kinase inhibitors (TKIs). Trastuzumab is the first target agent evidencing improvements in overall survival in
HER2-positive (human epidermal growth factor receptor 2) gastric cancer patients. Agents targeting vascular
epithelial growth factor (VEGF), mammalian target of rapamycin (mTOR), and other biological pathways are also
undergoing clinical trials, with some marginally positive results. Effective targeted therapy requires patient selection
based on predictive molecular biomarkers. Most phase III clinical trials are carried out without patient selection;
therefore, it is hard to achieve personalized treatment and to monitor patient outcome individually. The trend for
future clinical trials requires patient selection methods based on current understanding of GC biology with the
application of biomarkers.
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GC remains a major cancer burden across the globe. In
2008, approximately 989,000 new cases (7.8 % of global
cancer totals), and 738,000 deaths (9.7 % of global cancer
totals) occurred, making it the fourth most common ma-
lignancy and the second leading cause of cancer death
worldwide[1]. Geographically, Asian and South American
countries have a higher incidence rate of GC than the
United States and Western Europe. Though the absolute
incidence of GC has declined globally in the second half
of the 20th century, the relative incidence of proximal GC
has increased notably [2].
Traditional treatments, such as curative surgery, radio-
therapy, and perioperative chemotherapy, may improve
the survival rate of operable GC patients. However, most
patients are either diagnosed at an advanced stage or are
subject to relapse after prior curative surgery. For these
advanced patients, 5-FU (5-fluorouracil) cisplatin, or
their analogs remain standard treatment regimens, with
or without an anthracycline [3].* Correspondence: fudanlijin@163.com
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reproduction in any medium, provided the orIn the past decade, targeted therapies have signifi-
cantly impacted the treatment strategy of many common
malignancies, including breast, colorectal, and lung can-
cers. Unfortunately, research shows fewer encouraging
targeted treatments for GC than for other cancers. Re-
cently, Trastuzumab has been approved as standard care
for HER2-positive GC patients, according to the results of
clinical trials using ToGA (Trastuzumab for Gastric
Cancer) [4]. Many other molecular targeted agents are
also currently undergoing clinical trials, including VEGF
pathway targeting agents, other HER family targeting
agents, mTOR pathway inhibitors [5], and histone deace-
tylase (HDAC) inhibitors [6]. This review discusses recent
investigations of targeted agents for the treatment of
advanced GC.The Pathway of Targeted Therapy
Based on clinical outcomes from other malignancies,
many new treatment choices using targeted agents have
been studied in GC. Most targeted therapies focus on
the VEGF and epidermal growth factor receptor (EGFR)
related indications in advanced GC. Compounds against
novel targets, such as mTOR, c-Met (hepatocyte growth
factor receptor), and HDAC are also under investigation.
Table 1 lists current ongoing phase III trials of targeted
agents designed for the treatment of advanced GC.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Ongoing phase III trials of targeting agents for the treatment of advanced gastric cancer
ClinicalTrials.gov
Identifier





NCT00824785 1st line UK Open-label 730 OS EOX, EOX+panitumumab
NCT01248403 2nd line Germany Double blind 500 OS Paclitaxel, Paclitaxel + everolimus
NCT01170663 2nd line Global Double blinded 633 OS Placebo+ paclitaxel,
Ramucirumab+paclitaxel
NCT00450203 1st line UK Open Label 1100 OS ECX, ECX+ Bevacizumab
NCT00917384 2nd line Global Double blinded 315 OS Placebo+ BSC,
Ramucirumab+ BSC
NCT01512745 3rd line China Double blinded 500 PFS Placebo, Apatinib
OS, overall survival; PFS, progression-free survival; EOX, epirubicin, oxaliplatin and capecitabine; ECX, epirubicin, cisplatin and capecitabine.
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Angiogenesis, the growth of new blood vessels, is an im-
portant aspect of tumorigenesis that not only provides
tumor cells with nutrients and oxygen, but additionally
serves as a pathway for tumor cells to enter the circula-
tory system, where subsequent metastasis may occur [7].
Tumor angiogenesis is primarily modulated by VEGF A
and the receptors of VEGF (VEGFR) [8]. In GC, VEGF
expression is related to tumor aggressiveness and is ul-
timately an indicator for poor prognosis [9–15]. Anti-
VEGF agents have recently been developed, including
mAbs and TKIs, for the reasons mentioned above.Bevacizumab
Bevacizumab is a VEGF A blocking mAb currently under
investigation for the treatment of GC. Several phase II
trials combining bevacizumab with different chemother-
apeutic compounds were conducted on treatment-naive
patients with locally advanced or metastatic GC, or with
gastroesophageal junction cancer (GEJC), demonstrating
results which were initially promising [16–18]. On the
basis of results from these phase II studies, a phase III
randomized, double-blind, contrast study (AVAGAST)
was conducted internationally [19]. This study included
774 patients with previously untreated and locally
advanced or metastatic GC or GEJC. Patients were trea-
ted with capecitabine and cisplatin in combination with
either bevacizumab or a placebo. The median rate of
overall survival (OS) was 10.1 months for the placebo
group and 12.1 months for the bevacizumab group
(HR= 0.87; P = 0.1002), failing to meet the primary end-
point; however, significant improvement in progression-
free survival (PFS) and overall response rate (ORR) was
noted in the bevacizumab group. In subgroup analysis,
OS for the pan-American subgroup was 6.8 months for
placebo vs. 11.5 months for bevacizumab (HR=0.63).
For European and Asian-Pacific subgroups, OS was 8.6
vs. 11.1 months (HR=0.85), and 12.1 vs. 13.9 months
(HR=0.97), respectively, with all results favoring bevaci-
zumab. These results indicate that Pan-American patientsobtained the greatest benefit from the additional bevacizu-
mab treatment. The subgroup analysis of geographic
regions and GC subtypes was further reported in the 2012
American Society of Clinical Oncology (ASCO) gastro-
intestinal cancers symposium. For both Asian and non-
Asian patients, most patients have type 2 GC (52.1 %) or
type 3 (38.3 %) GC, and those with type 2 GC had worse
outcome than type 3 GC (median OS 10.3 vs 11.7 months;
HR=0.82; 95 % CI 0.68–1.00). For non-Asian patients,
prognosis is worse than Asian patients (8.0 vs 11.1 months;
HR=0.68; 95 % CI 0.53–0.89), and those with GC type 2
(6.5 vs 9.9 months; HR=0.68; 95 % CI 0.48–0.97) and type
3 (9.0 vs 11.7 months; HR=0.72; 95 % CI 0.48–1.07)
appear to benefit from bevacizumab, making bevacizumab
more promising in non-Asian patients [20].Ramucirumab
Ramucirumab is a fully humanzed mAb targeting
VEGFR2 [21]. Several trials are onging, including a ran-
domized phase II clinical trial of mFOLFOX6 (oxalipla-
tin, 5-FU, folic acid) chemotherapy plus Ramucirumab
versus mFOLFOX6 plus placebo for advanced gastro-
esophageal adenocarcinoma, a randomized phase III study
of paclitaxel with or without Ramucirumab in patients
with metastatic gastric adenocarcinoma after failure of
first-line therapy with platinum and fluoropyrimidine, and
another phase III study of Ramucirumab eing compared
with best supportive care (BSC) in patients with gastric
cancer and adenocarcinoma.Apatinib
Apatinib is a relatively "clean" TKI that selectively tar-
gets VEGFR-2 [22]. A randomized, three-arm phase II
trial of apatinib as a third-line treatment for patients
with advanced GC included 141 patients who received
apatinib (850 mg. qd.), apatinib (425 mg. bid.), or a pla-
cebo. The study was reported during the 2011 ASCO
Annual Meeting, as follows: ORR of 0 (placebo), 6.38
(apatinib 850 mg qd), and 13.04 % (apatinib 425 mg bid),
respectively [23]. The disease control rate was 10.42,
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3.4, and 3.4 months, respectively; the median OS was 2.5,
4.8, and 4.3 months, respectively. Primary adverse reac-
tions included hypertension and hand-foot syndrome. A
phase III clinical trial comparing apatinib to placebo in a
3rd-line setting in advanced GC is currently being con-
ducted in China. The enrollment target is 270. The
patients are randomized to apatinib 850 mg qd p.o. or pla-
cebo and are treaed until disease progression, intolerable
toxicity or withdrawal of consent. The trial was estimated
to be finished in June 2012.
Sorafenib
Sorafenib, originally developed for the treatment of kidney
cancer, is a multi-target TKI, targeting VEGFR, platelet-
derived growth factor receptor (PDGFR), and RAF path-
ways. It possesses two antineoplastic pathways: one acts
directly through the inhibition of tumor proliferation by
blocking the RAF/MEK/ERK-mediated cell signaling path-
way, and the other indirectly inhibits angiogenesis by
blocking VEGFR and PDGFR [24]. Based on the data
derived from hepatocellular carcinoma trials, several stud-
ies were designed to investigate the role of sorafenib in
advanced GC. The results of a phase II study of sorafenib
in combination with docetaxel and cisplatin as a treatment
for chemo-naive metastatic or local advanced unresectable
GC or GEJC patients has been reported [25]. The study
enrolled 44 patients who received sorafenib 400 mg bid, in
combination with docetaxel 75 mg/m2 d1 and cisplatin
75 mg/m2 on day 1 in a 21-day cycle. The ORR was 41 %,
the median PFS was 5.8 months, and the median OS was
13.6 months. The authors concluded that sorafenib, com-
bined with docetaxel and cisplatin, was effective and
tolerable as a treatment for GC or GEJC . However, this
study’s results did not indicate superiority over historical
data from the docetaxel and cisplatin combination chemo-
therapy, thereby prompting no further clinical develop-
ment of sorafenib in GC.
Sunitinib
Sunitinib blocks angiogenesis by inhibiting targets such
as VEGFR, PDGFR, RET and KIT. It is similar to sorafe-
nib in activity, as reported in different tumor types than
those observed in sorafenib treatment in both pre-
clinical and clinical settings [26]. In a phase II trial, suni-
tinib monotherapy was conducted on 52 patients with
chemo-refractory advanced GC, resulting in a median
OS of 5.8 months, displaying less effectiveness than
anticipated [27]. A single-arm, monotherapy phase II
study was performed in 78 patients as 2nd-line treat-
ment. Two patients (2.6 %) had partial responses and 25
patients (32.1 %) had a best response of stable disease
for ≥6 weeks. The median PFS was 2.3 months and me-
dian OS was 6.8 months. This study showed littleclinical value in monotherapy setting [28]. At this time,
there is no plan to move forward with sunitinib in fur-
ther clinical investigations of GC.
Cediranib
Cediranib, also known as AZD2171, is a highly potent
inhibitor of VEGFR-1 and VEGFR-2, which displays ac-
tivity against c-Kit and PDGFR-β [29]. A phase I study
of cediranib in combination with cisplatin plus fluoro-
pyrimidine (S-1 or capecitabine) was performed on 14
Japanese patients with treatment-naive advanced GC
[30]. This study demonstrated good tolerability with the
most common adverse side effects being decreased appe-
tite, fatigue and nausea. Furthermore, preliminary efficacy
evaluation showed one confirmed and three unconfirmed
partial responses that were ongoing at the time of data
cut-off. Further investigation is expected to continue in
the future.
EGFR-targeting agents
Epidermal growth factor receptor (EGFR) exists on the
cell surface and is activated by the binding of specific
ligands, including epidermal growth factor (EGF) and
transforming growth factor alpha. EGFR possesses an
intracellular tyrosine kinase domain that, upon activation,
may initiate downstream signaling, ultimately resulting in
DNA synthesis and cell proliferation. Inhibition of EGFR
activation disturbs downstream signaling and prevents
tumorigenesis [31]. The prognostic role of EGFR remains
controversial, and further investigation is needed [32–37].
Anti-EGFR mAbs and TKIs are currently undergoing clin-
ical trials for GC patients.
Cetuximab
Cetuximab is a chimeric (mouse/human) mAb targeting
to EGFR. Monotherapy with cetuximab for treatment of
advanced GC showed minimal activity [38]. Trials inves-
tigating cetuximab treatment after first-line chemothera-
pies were reported with moderate activities [39,40]. In
first-line settings (Table 2), in several phase II trials,
cetuximab has shown some encouraging results when
combined with various chemotherapeutic agents. Discrep-
ancies among these results may be due to the differences
in cytotoxic compounds. The phase III trial (EXPAND)
will assess the efficacy of cetuximab in combination with
cisplatin and capecitabine as a first-line treatment for
patients with advanced GC or GEJC. Results are expected
to be released later this year.
Panitumumab
Panitumumab is a fully humanized IgG2 mAb targeting
EGFR. Available data for panitumumab in GC is limited.
Based on data from metastatic colorectal cancer [52–54],
panitumumab was investigated in a dose-finding trial in
Table 2 Phase II, first-line clinical trials of cetuximab in combination with various chemotherapeutic agents
Agents n (tumor site) RR (%) PFS/TTP (month) OS (month)
mFOLFOX6+ cetuximab[41] 50 (GC) 50 5.5 9.9
Cisplatin + docetaxel + cetuximab[42] 72 (GC or GEJC) 41.2 5 9
Cetuximab+ FOLFOX4[43] 25 (GC) 36 6.5 10.6
Oxaliplatin + irinotecan + cetuximab[44] 51 (GC) 63 5.8 8.9
Oxaliplatin + folic acid + 5-FU+ cetuximab[45] 52 (GC) 65 7.6 9.5
Oxaliplatin + capecitabine+ cetuximab[46] 44 (GC) 52.3 6.5 11.8
Irinotican + folic acid + 5-FU+ cetuximab[47] 49 (GC or GEJC) 46 9 16.5
Epirubicin + cisplatin +5-FU+ cetuximab FOLFOX+ cetuximab
Irinotican + cisplatin + cetuximab[48]
245 (GC or GEJC) randomized 58 51 38 5.6 5.75 10 10 8.6
Cisplatin + 5-FU+ LV + cetuximab[49] 35 (GC) 68.6 11 14.5
Oxaliplatin + irinotecan + cetuximab[50] 51 (GC) 63 5.8 8.9
Docetaxel + oxaliplatin Docetaxel + oxaliplatin + cetuximab[51] 150 (GC or GEJC) randomized 24 29 4.7 5.1 9 8.5
Liu et al. Journal of Hematology & Oncology 2012, 5:31 Page 4 of 8
http://www.jhoonline.org/content/5/1/31gastric cancer to determine the optimal dosage when
combined with EOX regimen: epirubicin, oxaliplatin, and
capecitabine. Results indicated that a dose of 9 mg/kg of
panitumumab every 3 weeks, when combined with EOX,
meets the acceptable safety profile; it is currently being
used in an ongoing phase II/III REAL-3 trial, which is a
randomized, open-label trial of the efficacy of EOX with
or without Panitumumab as first line therapy for advanced
esophagogastric cancer [55].
HER2-targeting agent
HER2 is a cell membrane surface-bound receptor tyrosine
kinase that is normally involved in the signal transduction
pathway leading to cell growth and differentiation. The
reported expression of HER2 in GC patients and its cor-
relation with prognosis has varied across different studies
[34,56–58]. However, pre-clinical trials have shown the
efficacy of suppression of tumor growth in human GC
over-expressing HER2 by anti-HER2 antibody, making
HER2 a potential target [59,60]. Clinical investigation in
GC with HER2 targeting by either mAb or TKI has been
actively pursued.
Trastuzumab
Trastuzumab is a HER2 mAb that induces antibody-
dependent cellular cytotoxicity, inhibits HER2-mediated
signaling, and reduces the number of cell surface recep-
tors by increasing endocytosis [61]. A multi-center, ran-
domized, controlled phase III clinical study (ToGA) was
reported in 2010, with a total of 3807 advanced GC or
GEJC patients enrolled. Of these patients, 810 (21.2 %)
were positive for HER2 expression (FISH-amplified or
IHC 3+ and above). Among the 810 patients, 594 were
randomly assigned to receive chemotherapy treatment
(cisplatin plus 5-FU or capecitabine administered every
3 weeks for a maximum of 6 cycles) or chemotherapy
plus trastuzumab treatment (administered at a dose of8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg
every 3 weeks until the event of disease progression,
unacceptable toxicity or consent withdrawal). Median
OS was 13.8 months in patients assigned to trastuzu-
mab plus chemotherapy, compared with 11.1 months
in those assigned to chemotherapy alone (HR 0.74; 95 % CI
0.60 - 0.91; p= 0.0046). The efficacy result translated into a
26 % reduction in the death rate. Adverse effects were com-
parable between the two treatment groups [4]. Based on
the findings of this trial, trastuzumab, in combination
with chemotherapy has been approved by US FDA and
European Medicines Agency as first-line therapy in HER2
positive GC and GEJC. Notably, HER2-positivity rates were
found to be significantly higher in GEJC than GC (33.2 %
vs 20.9 %; p< 0.001), and in intestinal than diffuse/mixed
cancer (32.2 % vs 6.1 %/20.4 %; p< 0.001) [62].
Lapatinib
Lapatinib is an oral TKI which inhibits both EGFR and
HER2 kinases. The phase II trial of lapatinib monotherapy
as first-line therapy in 47 patients with advanced GC
demonstrated excellent tolerability and moderate activity
(median time to treatment failure was 1.9 months and OS
was 4.8 months). Analyzing potential biomarkers revealed
that patients with higher HER2 or lower interleukin-8
gene expression levels experienced prolonged OS [63]. In
a phase II trial of capecitabine and lapatinib combination
as first-line treatment in 58 patients with GC (76 %) or
GEJC (24 %), 24 % of patients showed partial responses
(17 % confirmed, 7 % unconfirmed), 36 % showed disease
stabilization and 26 % showed disease progression [64].
The LOGiC study (Lapatinib Optimization Study in HER2
Positive Gastric Cancer), a phase III global study, designed
to evaluate clinical endpoints and safety of chemotherapy
plus lapatinib, has reached its accrual goal and is ongoing
for follow up. Efficacy data is anticipated to be released in
late 2012. An ongoing TYTAN trial is a randomized,
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with Paclitaxel versus Paclitaxel alone in the second line
setting of erbB2 amplified advanced GC.
Other targeted agents
Everolimus
The mTOR is involved in several important intracellular
signal transduction pathways that regulate cell survival,
hyperplasia, apoptosis, and other important physiological
functions critical to tumorigenesis and cancer develop-
ment, thus providing as a potential anti-cancer therapy
[65]. The first mTOR targeting agent was everolimus, an
oral mTOR serine/threonine kinase inhibitor, whose
anti-GC activity was observed in both pre-clinical and
phase I studies [65–67]. In a phase II study of everoli-
mus in 53 patients with previously treated metastatic
gastric cancer, the results showed that the DCR was
56.0 % (95 % CI, 41.3 % to 70.0 %) and median PFS was
2.7 months (95 % CI, 1.6 to 3.0 months). At a median
follow-up of 9.6 months, the median OS was 10.1 months
(95 % CI, 6.5 to 12.1 months) and good tolerability was
noted [68]. Based on the promising results from several
phase II trials, an international phase III trial was
launched in June 2009. A total of 656 patients with
advanced GC previously treated with 1 or 2 lines of sys-
temic chemotherapy from 23 countries were randomly
treated with everolimus or BSC plus a placebo. Data
released from the 2012 ASCO Gastrointestinal Cancers
Symposium indicated that the median OS was 5.4 months
with everolimus, vs. 4.3 months with placebo treatment
(HR, 0.90; 95 % CI, 0.75-1.08; P = 0.1244) [69]. Median
PFS per local investigator assessment was 1.7 months with
everolimus vs. 1.4 months with placebo (HR, 0.66; 95 %
CI, 0.56-0.78; p< 0.0001). PFS was improved significantly
by everolimus, although the OS was not.
Onartuzumab
c-Met is an oncogene encoding a membrane tyrosine
kinase receptor – hepatocyte growth factor receptor
(HGFR). HGFR plays an important role in tumor develop-
ment through activation of key oncogenic pathways,
angiogenesis, and tumor metastasis [70]. In gastric cancer
patients, amplification and expression of c-Met often indi-
cates poor prognosis [71–74]. Several types of targeted
agents have been developed for c-Met pathway. Onartuzu-
mab is a humanized monoclonal antibody directed against
HGFR. A phase II clinical trial of Onartuzumab in com-
bination with mFOLFOX6 in patients with metastatic
HER2-negative gastro-esophageal cancer is to be launched
soon.
Vorinostat
Vorinostat is a HDAC inhibitor, also known as suberoy-
lanilide hydroxamic acid. Pre-clinical studies have shownthat vorinostat has potential anti-GC activity, due to a
synergistic effect exhibited when combined with taxane
[75,76]. A phase I/II study of vorinostat plus capecita-
bine and cisplatin is currently recruiting patients for first
line treatment of metastatic or recurrent GC.
Future Perspectives
Contemporary targeted cancer therapy has progressed
rapidly over the past decade. Unfortunately, GC remains
a major challenge with fewer encouraging targeted treat-
ments than other cancers have. The addition of trastuzu-
mab to combination chemotherapy is now considered a
standard first-line treatment for HER2 positive advanced
GC patients, and this treatment is still under investiga-
tion for potential use in perioperative settings [4]. Lapa-
tinib is currently the most promising new agent for
treatment of gastric cancer, in the light of the ToGA
trial. Agents targeting human EGFR remain very contro-
versial in treating gastric cancer. Cetuximab has exhibited
the potential for GC treatment, which functions by bind-
ing to the ubiquitous HER1(EGFR); based on success in
treating colorectal cancer patients, cetuximab is currently
one of the promising new candidates for treatment of gas-
tric cancer due to its very low mutation rate of K-RAS.
Anti-angiogenic therapy has achieved successful results
in several cancer types, including colorectal, hepatocellu-
lar, and kidney cancer; however, despite tremendous effort
in the past decade, many trials demonstrated only mar-
ginal effectiveness over existing treatments. An AVA-
GAST trial recently released results, indicating negative
OS data [19] similar to study results from sorafenib and
sunitinib. The primary reason for the disappointing results
of anti-angiogenesis treatment is the lack of predictive
biomarkers for the investigated drugs. Although biomar-
kers such as serum VEGFA and microvessel density have
repeatedly been cited as potentially useful predictive mar-
kers for the effectiveness of anti-angiogenic therapy, they
remain unconfirmed by any phase III trial. This makes it
difficult to determine which agents are potentially most
beneficial to certain patients. Based on the results of the
investigations in lung cancer and breast cancer, further
clinical analysis of biomarkers may lead to a better under-
standing of GC outcomes and appropriate treatment selec-
tion. Not limited to anti-angiogenic therapy, “Personalizing
cancer care” is the goal for all targeting agents, in order to
achieve both improved and optimal results based on ef-
fective biomarker selection [77].
The majority of existing targeting agents focus on both
EGF/VEGF and their receptors, but contemporary research
has revealed many new pathways related to tumor angio-
genesis and proliferation, providing numerous new poten-
tial targets. Trials are already underway to test potential
targeting agents focusing on the downstream components
of VEGFR/EGFR, such as inhibitors of mTOR, c-Met, and
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longed PFS at ASCO Gastrointestinal Cancers Symposium
this year.
Drug resistance is a critical issue in the development
of targeted agents. Effective treatment may involve a
combination of different targeted agents, chemothera-
pies, or it may require the use of target agents as part of
a complex approach to cancer treatment utilizing mul-
tiple modalities.
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